You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK):传奇生物第四季度收益大增110% 全年研发开支达2.32亿美元
格隆汇 03-18 20:52

格隆汇3月8日丨金斯瑞生物科技(01548.HK)公告,截至2020年12月31日止年度,公司附属传奇生物科技股份有限公司取得收益7567.6万美元,同比增长32.15%;期间研发开支达2.32亿美元,同比增长43.36%。

截至2020年12月31日止3个月,传奇生物收益为4080万美元,上年同期为1950万美元,同比增长110%。增加2130万美元主要是由于确认因根据传奇生物与杨森的协议实现额外里程牌的付款而获得的更多收益,并解除相关受限制可变代价。

研发开支同比增加主要是由于该年度临床试验数量增加、参加有关试验的患者人数增加及研发候选产品数量增加。

传奇生物首席执行官及首席财务官黄颖博士表示:“今年是传奇生物决定性的一年,传奇生物实现了重要的管线进展,并完成了首次公开发售和在纳斯达克上市。尽管新冠肺炎疫情带来挑战,但传奇生物在2020年仍然表现强劲,且2021年延续了这一势头,肿瘤管线计划取得重大进展。通过与杨森生物科技有限公司(杨森)的合作,传奇生物在2020年启动了西达基奥仑赛(cilta-cel)的全球三期研究,并作为综合临床开发计划的一部分扩展了多队列二期研究,包括用于治疗早期多发性骨髓瘤。2021年,公司预计将在推进cilta-cel的监管审批程序中实现重要的里程碑”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account